

Edgar Filing: AnorMED Inc. - Form SC 13D/A

AnorMED Inc.
Form SC 13D/A
May 10, 2006

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D
Under the Securities Exchange Act of 1934

(Amendment No. 7)

ANORMED, INC.

(Name of Issuer)

Common Stock, no par value per share

(Title of Class of Securities)

035910108

(CUSIP Number)

Leo Kirby
667 Madison Avenue, 19th Floor
New York, NY 10021
(212) 521-2418

(Name, Address and Telephone Number of Person Authorized
to Receive Notices and Communications)

April 21, 2006

(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box.

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 (the "Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Edgar Filing: AnorMED Inc. - Form SC 13D/A

Page 1 of 7 Pages

SCHEDULE 13D

CUSIP No. 035910108

Page 2 of 7 Pages

1 NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS

Julian C. Baker

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

(a)

(b)

3 SEC USE ONLY

4 SOURCE OF FUNDS (See Instructions)

WC

5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO
ITEMS 2(d) OR 2(e)

6 CITIZENSHIP OR PLACE OF ORGANIZATION

United States

NUMBER OF 7 SOLE VOTING POWER
SHARES

BENEFICIALLY 0
OWNED BY

EACH 8 SHARED VOTING POWER
REPORTING

PERSON 9,411,500
WITH

9 SOLE DISPOSITIVE POWER

0

10 SHARED DISPOSITIVE POWER

9,411,500

11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

9,411,500

12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
(See Instructions)

13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

Edgar Filing: AnorMED Inc. - Form SC 13D/A

22.9%

14 TYPE OF REPORTING PERSON (See Instructions)
IN

SCHEDULE 13D

CUSIP No. 035910108

Page 3 of 7 Pages

1 NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS

Felix J. Baker

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

(a)

(b)

3 SEC USE ONLY

4 SOURCE OF FUNDS (See Instructions)

WC

5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO
ITEMS 2(d) OR 2(e)

6 CITIZENSHIP OR PLACE OF ORGANIZATION

United States

NUMBER OF 7 SOLE VOTING POWER
SHARES

BENEFICIALLY 25,000

OWNED BY

EACH 8 SHARED VOTING POWER

REPORTING 9,411,500

PERSON

WITH

9 SOLE DISPOSITIVE POWER

25,000

10 SHARED DISPOSITIVE POWER

9,411,500

11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

9,436,500

12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
(See Instructions)

Edgar Filing: AnorMED Inc. - Form SC 13D/A

13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

22.9%

14 TYPE OF REPORTING PERSON (See Instructions)

IN

This Amendment No. 7 to Schedule 13D is being filed by Julian C. Baker and Felix J. Baker (the "Reporting Persons") to amend and supplement the statement on Schedule 13D previously filed by them, as heretofore amended, with respect to the common stock, no par value (the "Common Stock"), of AnorMED, Inc. (the "Company"). Except as amended and supplemented hereby, that statement remains in full force and effect.

Item 4. Purpose of Transaction.

At the shareholders' meeting of the Company on April 21, 2006, the slate of directors nominated by the Reporting Persons was elected by the shareholders, and immediately after the shareholders' meeting the Board of Directors elected two additional directors. The Board of Directors now consists of the following persons:

- o Dr. Michael Abrams, President and Chief Executive Officer of the Company
- o Felix J. Baker, Ph.D., Managing Member of Baker Bros. Advisors, LLC
- o Joseph P. Dougherty, Ph.D., Managing Director of Seaview Securities LLC
- o Henry Fuchs, M.D., Ph.D., Executive Vice President and Chief Medical Officer, Onyx Pharmaceuticals Inc.
- o Kenneth Galbraith, President, Gigha Consulting Ltd. and Chairman of the Board of the Company
- o Dr. William Hunter, Chief Executive Officer of Angiotech Pharmaceuticals Inc.
- o Jacques R. Lapointe, Chairman, Conjuchem Inc.
- o I. Berl Nadler, Partner, Davies Ward Phillips & Vineberg LLP
- o Kelvin Neu, M.D., Associate, Baker Bros. Advisors, LLC
- o Klaus Veitinger, M.D., Ph.D., Member of the Executive Board and Chief Executive Officer, U.S. & Asian Operations, Schwarz Pharma AG

As a result of these events, the Reporting Persons no longer have any disagreements with the Board of Directors of the Company. At this time the entities named in Item 5 are holding the shares of Common Stock solely for investment. The Reporting Persons expect to review from time to time the investment positions of these entities and may, depending on market and other conditions, increase or decrease their holdings.

Whether the entities purchase any additional shares of Common Stock or dispose of any shares of Common Stock, and the amount and timing of any such transactions, will depend upon the Reporting Persons' continuing assessments of pertinent factors, including the availability of shares of Common Stock for purchase at particular price levels, the Company's business and prospects, other business investment opportunities, economic conditions, stock market conditions, money market conditions, the attitudes and actions of the Board of Directors and management of the Company, the availability and nature of opportunities to dispose of shares in the Company and other plans and requirements of the particular entities. Depending upon their assessments of these factors from time to time, the Reporting Persons may change their present intentions as stated above, including determining to acquire additional shares of Common Stock (by

Edgar Filing: AnorMED Inc. - Form SC 13D/A

means of open market or privately negotiated purchases) or to dispose of some or all of the shares of Common Stock under their control. The Reporting Persons do not have any plans or proposals with respect to any extraordinary corporate transaction involving the Company or any sale of its assets or any change in its Board of Directors, management, capitalization, dividend strategy, charter or by-laws, or any other change in its business or corporate structure or with respect to the delisting or deregistration of any of its securities including, without limitation, those matters described in subparagraphs (a) through (j) of Item 4 of Schedule 13D. Felix J. Baker, one of the Reporting Persons, is a director of the Company.

Item 5. Interest in Securities of the Issuer.

Set forth in the table below is the aggregate number of shares of Common Stock owned, including shares that may be acquired upon the exercise of options by each of the following on December 8, 2005, together with the percentage of outstanding shares of Common Stock that such ownership represents based upon 41,222,039 shares outstanding as reported on the Company's March 22, 2006 proxy circular.

Page 4 of 7 Pages

Name	Number of Shares	Percent of Class Outstanding
Baker Bros. Investments, L.P.	330,058	0.8%
Baker Bros. Investments II, L.P.	351,749	0.9%
Baker Biotech Fund I, L.P.	3,604,520	8.7%
Baker Brothers Life Sciences, L.P.	5,013,859	12.2%
14159, L.P.	83,137	0.2%
Baker/Tisch Investments, L.P.	28,177	0.1%
Felix J. Baker	25,000	0.0%
Total	9,436,500	22.9%

By virtue of their ownership of entities that have the power to control the investment decisions of the limited partnerships listed in the table above, Julian C. Baker and Felix J. Baker may each be deemed to be beneficial owners of shares owned by such entities and may be deemed to have shared power to vote or direct the vote of and shared power to dispose or direct the disposition of such securities.

Item 7. Material To Be Filed as Exhibits.

Exhibit 1 Agreement regarding the joint filing of this statement.

Page 5 of 7 Pages

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

May 9, 2006

Edgar Filing: AnorMED Inc. - Form SC 13D/A

By: /s/ Julian C. Baker

Julian C. Baker

By: /s/ Felix J. Baker

Felix J. Baker

Page 6 of 7 Pages

EXHIBIT 1

AGREEMENT

In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that this Statement on Schedule 13D relating to the Common Stock, no par value, of Anormed Inc. is being filed with the Securities and Exchange Commission on behalf of each of them.

May 9, 2006

By: /s/ Julian C. Baker

Julian C. Baker

By: /s/ Felix J. Baker

Felix J. Baker

Page 7 of 7 Pages